The 2nd Edition of International Cancer and Precision Oncology Conference (ICPOC 2026) is delighted to welcome Dr. Tanja Obradovic, Strategy Consultant and internationally recognized oncology drug development expert, as a featured speaker.
With more
than 20 years of experience in oncology pharmaceutical development, Dr.
Obradovic has played a significant role in advancing innovative cancer
therapies across multiple stages of clinical development.
Presentation Title
About the Session
The rapid
advancement of immunotherapy, cell therapy, and gene therapy has transformed
oncology drug development, creating new opportunities while introducing greater
complexity in clinical research.
Selecting
the right Clinical Research Organization (CRO) has become a critical strategic
decision for biopharmaceutical companies seeking efficient clinical execution,
regulatory compliance, and successful global development.
During
her presentation, Dr. Obradovic will discuss practical strategies for
identifying and evaluating CRO partners capable of supporting modern oncology
clinical trials.
Key Learning Points
- Evaluating CRO expertise for
oncology clinical trials
- Matching CRO capabilities
with product development stages
- Meeting regulatory
expectations for successful clinical development
- Assessing strategic
execution, feasibility, and risk management
- Evaluating project
management and quality systems
- Key considerations for
oncology products entering the US market
- Determining the optimal
timing for CRO engagement
- Best practices for selecting
long-term strategic development partners
About Dr. Tanja Obradovic
Dr. Tanja
Obradovic brings over two decades of leadership experience in oncology
pharmaceutical development.
She held
senior leadership roles at Merck, where she contributed extensively to
the development, regulatory approvals, and lifecycle management of Keytruda
across multiple cancer indications, including melanoma, lung cancer, and
women's cancers.
She later
led innovative drug and cell therapy development at Takeda before
serving as Vice President of Drug Development Services and Scientific
Affairs within Medical Strategy at ICON.
Currently,
she serves as a Strategy Consultant and advises several biotechnology companies
on oncology drug development and clinical strategy.
Join ICPOC 2026
ICPOC
2026 will bring together renowned scientists, clinicians, pharmaceutical
leaders, and healthcare innovators to discuss the latest advances in cancer
research and precision oncology.
📅 Date: November 23–25, 2026
📍 Venue: Singapore & Online
🌐 Website: https://cancer.miconferences.com/
📄 Submit Your Abstract:
https://cancer.miconferences.com/abstract-submission
Join us
for three days of scientific excellence, collaboration, and innovation shaping
the future of cancer care.
#ICPOC2026
#ClinicalResearch #CancerResearch #DrugDevelopment #ClinicalTrials #Oncology
#PrecisionMedicine #Biopharma #CRO #Immunotherapy
